Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimizing maintenance therapy in acute myeloid leukemia: where do we stand in the year 2024?
Alati C, Pitea M, Mico MC, Marafioti V, Greve B, Pratico G, Loteta B, Cogliandro F, Porto G, Policastro G, Utano G, Sgarlata A, Imbalzano L, Delfino IM, Montechiarello E, Germano J, Filippelli G, Martino M. Alati C, et al. Among authors: martino m. Expert Rev Hematol. 2024 Aug;17(8):515-525. doi: 10.1080/17474086.2024.2382300. Epub 2024 Jul 21. Expert Rev Hematol. 2024. PMID: 39017205 Review.
High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.
Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P. Martino M, et al. Am J Hematol. 2006 Dec;81(12):973-8. doi: 10.1002/ajh.20677. Am J Hematol. 2006. PMID: 16888786 Free article. Clinical Trial.
Tolerability and efficacy of busulfan and fludarabine as allogeneic pretransplant conditioning therapy in acute myeloid leukemia: comparison with busulfan and cyclophosphamide regimen.
Fedele R, Messina G, Martinello T, Gallo GA, Pontari A, Moscato T, Console G, Dattola A, Princi D, Cuzzola M, Alati C, Ronco F, Molica S, Irrera G, Martino M. Fedele R, et al. Among authors: martino m. Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):493-500. doi: 10.1016/j.clml.2014.04.006. Epub 2014 Jun 11. Clin Lymphoma Myeloma Leuk. 2014. PMID: 25034142
A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.
Martino M, Ciavarella S, De Summa S, Russo L, Meliambro N, Imbalzano L, Gallo GA, Moscato T, Messina G, Ferreri A, Cuzzola M, Irrera G, Naso V, Cimminiello M, Console G, Loseto G, Tommasi S, Guarini A. Martino M, et al. Biol Blood Marrow Transplant. 2018 Mar;24(3):608-613. doi: 10.1016/j.bbmt.2017.09.021. Epub 2017 Oct 13. Biol Blood Marrow Transplant. 2018. PMID: 29032271 Free article. Clinical Trial.
Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts.
Martino M, Gori M, Moscato T, Naso V, Ferreri A, Provenzano F, Loteta B, Sanguedolce MC, Console G, Dattola A, Pucci G, Gentile M, Morabito A, Recchia AG, Tripepi G, Pitino A. Martino M, et al. Biol Blood Marrow Transplant. 2019 Aug;25(8):1586-1591. doi: 10.1016/j.bbmt.2019.04.011. Epub 2019 Apr 17. Biol Blood Marrow Transplant. 2019. PMID: 31002994 Free article. Clinical Trial.
A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant.
Martino M, Gori M, Tripepi G, Recchia AG, Cimminiello M, Provenzano PF, Naso V, Ferreri A, Moscato T, Console G, Loteta B, Gallo GA, Gentile M, Innao V, Rossi M, Morabito A, Vincelli ID, Mannina D, Pitino A. Martino M, et al. Ann Hematol. 2020 Feb;99(2):331-341. doi: 10.1007/s00277-019-03901-w. Epub 2019 Dec 18. Ann Hematol. 2020. PMID: 31853703 Clinical Trial.
Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy.
Mariotti J, Raiola AM, Evangelista A, Carella AM, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, Brunello L, Merla E, Savino L, Loteta B, Console G, Fanin R, Sperotto A, Marano L, Marotta S, Frieri C, Sica S, Chiusolo P, Harbi S, Furst S, Santoro A, Bacigalupo A, Blaise D, Angelucci E, Mavilio D, Castagna L, Bruno B. Mariotti J, et al. Among authors: martino m. Blood Adv. 2020 Aug 25;4(16):3900-3912. doi: 10.1182/bloodadvances.2020001620. Blood Adv. 2020. PMID: 32813875 Free PMC article.
2,339 results